<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04682795</url>
  </required_header>
  <id_info>
    <org_study_id>2020-811</org_study_id>
    <nct_id>NCT04682795</nct_id>
  </id_info>
  <brief_title>Comparison of Safety and Efficacy of Needle-Free Injector and Insulin Pen in Patients With T2DM</brief_title>
  <official_title>A Prospective, Multi-center, Randomized, Open-label, Parallel Group Study to Evaluate Safety and Efficacy of Needle-free Injector Versus Insulin Pen in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective, multi-center, randomized, open-label, parallel group trial, the safety&#xD;
      and efficacy of needle-free injector will be compared with insulin pen after 2 weeks of&#xD;
      treatment in patients with type 2 diabetes. This trial will enable assessment of the&#xD;
      clinically relevant endpoint of a change in Time in Range (TIR), a newly recommended&#xD;
      measurement of blood glucose fluctuations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the current study is to investigate the efficacy, safety and tolerability of&#xD;
      needle-free injector compared to conventional insulin pen given for 2 weeks as the insulin&#xD;
      carrier in patients with type 2 diabetes mellitus. The primary endpoint in this study is the&#xD;
      change from baseline in TIR (after 2 weeks of treatment) in all patients with baseline and at&#xD;
      least one post baseline measurement. Patients with type 2 diabetes who meet the entry&#xD;
      criteria are planned for inclusion in this trial. Approximately 200 patients will be enrolled&#xD;
      in the study. Patients who qualify will be randomized to needle-free injector group or&#xD;
      conventional insulin pen group. Duration of treatment includes 1-week screening period,&#xD;
      2-week treatment observation period and 2-week follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time In Range</measure>
    <time_frame>2 weeks</time_frame>
    <description>Time In Range (TIR, 3.9-10mmol/L)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to occurrence of treat to target</measure>
    <time_frame>2 weeks</time_frame>
    <description>Fasting glucose on treatment &lt;7mmol/L and non-fasting glucose &lt;10mmol/L, or TIR &gt;70% (SMBG or FCGM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of a treat to target response and without any hypoglycemic episodes</measure>
    <time_frame>2 weeks</time_frame>
    <description>Occurrence of a treat to target response and without any hypoglycemic episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D Health Questionnaire</measure>
    <time_frame>2 weeks</time_frame>
    <description>the EQ-5D descriptive system The change from baseline after 2 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-VAS Health Questionnaire</measure>
    <time_frame>2 weeks</time_frame>
    <description>the EQ-VAS. The change from baseline after 2 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form 36 (SF-36)</measure>
    <time_frame>2 weeks</time_frame>
    <description>The change from baseline after 2 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin dose</measure>
    <time_frame>2 weeks</time_frame>
    <description>The change from baseline after 2 weeks of treatment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Insulin treatment compliance</measure>
    <time_frame>2 weeks</time_frame>
    <description>Recording whether the subjects obey the program to inject insulin at the specified time point in the 1st, 2nd, 3rd visit. Compliance will be calculated according to the formula: Compliance(%) = （Number of injections actually administered /Number of injections which should have been administered in the same period）*100%</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>T2DM (Type 2 Diabetes Mellitus)</condition>
  <condition>Needle-free Injector</condition>
  <condition>Time in Range</condition>
  <arm_group>
    <arm_group_label>Needle-free injector group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To evaluate the efficacy and safety of the needle-free injector in T2DM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin pen group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To evaluate the efficacy and safety of the insulin pen in T2DM</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Needle-free injector</intervention_name>
    <description>Using needle-free injector as insulin carrier to treat T2DM</description>
    <arm_group_label>Needle-free injector group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Insulin pen</intervention_name>
    <description>Using insulin pen as insulin carrier to treat T2DM</description>
    <arm_group_label>Insulin pen group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥ 18 and ≤75 years with type 2 diabetes;&#xD;
&#xD;
          -  HbA1c ≥ 7.5 to ≤11.0%;&#xD;
&#xD;
          -  Receipt of premixed insulin and/or oral anti-diabetic agents ≥ 12 weeks before&#xD;
             enrollment in the study, and insulin dose adjustments ≤ 10% within 4 weeks before&#xD;
             enrollment (dose adjustment = (the maximum dose within a month - the minimum dose) /&#xD;
             Final dose (dose of the day before the visit) × 100%);&#xD;
&#xD;
          -  BMI ≤ 32kg / m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with any of the following conditions will be excluded:&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Severe hypoglycemia within one month; diabetic ketoacidosis or hyperosmotic diabetic&#xD;
             status within 6 months prior to informed consent&#xD;
&#xD;
          -  Myocardial infarction, stroke or other severe cardiovascular events within 6 months&#xD;
             prior to informed consent&#xD;
&#xD;
          -  Current treatment with systemic steroids or immunosuppressive agents, or have&#xD;
             immunologic deficiency disease at time of informed consent&#xD;
&#xD;
          -  Severe mental instability, or alcohol abuse, or drug abuse&#xD;
&#xD;
          -  Skin lesions at the insulin injection site&#xD;
&#xD;
          -  Cancer within 5 years prior to informed consent&#xD;
&#xD;
          -  Pancreatitis of severe infectious diseases within 1 months prior to informed consent&#xD;
&#xD;
          -  Known hypersensitivity or allergy to the insulin&#xD;
&#xD;
          -  Renal impairment (CKD-EPI eGFR&lt;60ml/min)&#xD;
&#xD;
          -  Impaired hepatic function, defined by serum levels of either ALT (SGPT), AST (SGOT),&#xD;
             or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined&#xD;
&#xD;
          -  Participation in another trial within 2 months prior to informed consent&#xD;
&#xD;
          -  Patients that investigators believe may fail to complete the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuezhong Ren, MD</last_name>
    <phone>+8657189713764</phone>
    <email>renyuez@zju.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>2nd Affiliated Hospital, School of Medicine, Zhejiang University, Changxing Campus</name>
      <address>
        <city>Changxing</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jing Li</last_name>
      <phone>15306821602</phone>
      <email>tom427@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Hangzhou Normal University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lan Shou</last_name>
      <phone>18958137771</phone>
      <email>358897118@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>2nd Affiliated Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuezhong Ren</last_name>
      <phone>+8657189713764</phone>
      <email>renyuez@zju.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Yuezhong Z Ren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hangzhou First People's Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xianfeng Zhang</last_name>
      <phone>13858023138</phone>
      <email>zxf2541@zju.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The 2nd Affiliated Hospital of Zhejiang Chinese Medical University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jiang Hu</last_name>
      <email>zjsxhyygcp@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Xiaoshan</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jun Chen</last_name>
      <phone>15925676818</phone>
      <email>64774630@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huzhou Central Hospital</name>
      <address>
        <city>Huzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianping Yao</last_name>
      <phone>13567288210</phone>
      <email>gtl52@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jiaxing</name>
      <address>
        <city>Jiaxing</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qiang Zhou</last_name>
      <phone>15990351200</phone>
      <email>jxsdyyyqx@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jinhua Municipal Central Hospital Medical Group</name>
      <address>
        <city>Jinhua</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Huaying Huang</last_name>
      <phone>13516970225</phone>
      <email>13516970225@139.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lanxi People's Hospital</name>
      <address>
        <city>Lanxi</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaochun Lan</last_name>
      <phone>13600694315</phone>
      <email>LXYYLXC@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lishui People's Hospital</name>
      <address>
        <city>Lishui</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Riqiu Chen</last_name>
      <phone>18957091378</phone>
      <email>zjlscrq321@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ningbo First Hospital</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shengnan Xu</last_name>
      <phone>13429253237</phone>
      <email>304494753@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ningbo Medical Center Lihuili Hospital</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lingling Fang</last_name>
      <phone>13958297977</phone>
      <email>cxyangy@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated People's Hospital of Ningbo University</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weishen Gong</last_name>
      <phone>13958236139</phone>
      <email>gongwk@vip.126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Quzhou People's Hospital</name>
      <address>
        <city>Quzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chaohui Hu</last_name>
      <phone>15605709398</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shangyu People's Hospital of Shaoxing</name>
      <address>
        <city>Shaoxing</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weiping Tu</last_name>
      <phone>13858586136</phone>
      <email>605114744@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Shaoxing University</name>
      <address>
        <city>Shaoxing</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Huizhen Zhou</last_name>
      <phone>13983552029</phone>
      <email>844966981@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taizhou Hospital</name>
      <address>
        <city>Taizhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zuhua Gao</last_name>
      <phone>13586151069</phone>
      <email>gaozh@enzemed.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tongxiang First Hospital</name>
      <address>
        <city>Tongxiang</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fenjuan Xu</last_name>
      <phone>13819057620</phone>
      <email>xufenjuan2001@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Wenling</name>
      <address>
        <city>Wenling</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Haiyang Lin</last_name>
      <phone>13867617958</phone>
      <email>13609380@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhoushan Hospital</name>
      <address>
        <city>Zhoushan</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yan Jing</last_name>
      <phone>17858292396</phone>
      <email>euginia1976@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 16, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

